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Abstract Lynch Syndrome (LS) is a cancer susceptibility
syndrome caused mostly by mutations in the mismatch
repair genes, hMLH1, hMSH2 and hMSH6. Mutation
carriers are at risk of colorectal and endometrial cancer
and, less frequently, cancer of the ovaries, stomach, small
bowel, hepatobiliary tract, ureter, renal pelvis and brain.
The influence of environmental factors on extracolonic
cancer risk in LS patients has not been investigated thus
far. The aim of this study was to investigate some of these
factors in South African females carrying the hMLH1
c.C1528T mutation and their mutation-negative relatives.
Data were collected from 87 mutation-positive females and
121 mutation-negative female relatives regarding age,
cancer history, hormonal contraceptive use, parity, duration
of breast feeding, height, weight and age at first birth, last
birth, menarche and menopause. Influence of these factors
on cancer risk was analysed by mixed-effects generalised
linear models. Extracolonic cancer occurred in 14% (12/
87) of mutation-positive females versus 7% (8/121) of
mutation-negative females, (P = 0.0279, adjusted for age
and relatedness between women). Breast cancer was the
most common extracolonic cancer. An association was
found for oral contraceptive use and extracolonic cancer
risk in mutation-negative females only. No association was
found for any of the other risk factors investigated, when
adjusted for age. This might be due to the scarcity of
extracolonic cancers in our data. Future knowledge on the
influence of additional environmental factors on cancer risk
in LS females can lead to evidence-based lifestyle advice
for mutation carriers, thereby complementing the preven-
tion strategies available today. In addition, it can contribute
to an integrated model of cancer aetiology. Therefore, this
study should be taken as a thrust for further research.
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Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC) or
Lynch syndrome (LS) is a cancer susceptibility syndrome
caused mostly by mutations in the mismatch repair genes,
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hMLH1, hMSH2 and hMSH6. Colorectal and endometrial
cancers are the cancer types most frequently reported;
mutation carriers are at an estimated lifetime risk of up to
70 and 27–71%, respectively [1, 12, 23, 33, 34]. In addi-
tion, cancers of the ovaries, stomach, small bowel, hepa-
tobiliary tract, ureter, renal pelvis and brain are part of the
HNPCC tumour spectrum [35, 38].
Surveillance programs in LS patients aiming at colo-
rectal cancer are highly effective [17, 30]. Yet, the avail-
able screening methods for gynaecologic cancer are
unreliable [11, 27, 28, 32]. Prevention programs aiming to
modify environmental risk factors have not been estab-
lished thus far, very likely because such factors have not
been adequately identified.
In LS, expression of disease is very heterogeneous. This
phenotypic heterogeneity has been attributed to genetic and
allelic heterogeneity and the influence of sex, genetic
modifiers and environmental factors [10, 13, 14, 16, 18, 24,
33, 37]. Investigations regarding the influence of environ-
mental factors on phenotypic expression in LS mutation
carriers have been limited to colorectal cancer risk only,
and the cohorts investigated were generally small [10, 19,
36, 37].
In South Africa, a relatively large ‘homogeneous’ cohort
predisposed to LS has been described previously, consist-
ing of 15 families carrying the hMLH1 c.C1528T mutation
[26, 30, 31]. Prior research in this cohort has investigated
the occurrence of extracolonic cancers and the influence of
modifier genetic factors on age of cancer onset and cancer
diagnosis [3, 13]. Notably, breast cancer was the most
common extracolonic cancer in the cohort.
In the general population, several environmental risk
factors are known to affect breast cancer risk. Early age at
menarche, late age at menopause, postmenopausal obesity,
high age at first birth, low age at last birth and oral con-
traceptive use are positively associated, whereas long
duration of breastfeeding, premenopausal obesity and high
parity are inversely associated [15]. The risk of endometrial
and ovarian cancer is raised by nulliparity, early menarche,
late menopause and obesity, whereas oral contraceptive use
has a protective effect on ovarian and endometrial cancer
risk. Other factors have been associated with these cancers
but show inconclusive results, including short duration of
breastfeeding, older age at first birth and young age at last
birth [2, 9].
As it was assumed that breast, endometrial and ovarian
cancers would be the most common extracolonic cancers in
our cohort, we investigated the influence of environmental
factors known to be important in these cancer types in
females carrying the hMLH1 c.C1528T mutation.
A recent study on mutation-negative first degree family
members of BRCA-mutation carriers, showed them to be at
an elevated risk for breast cancer when compared to the
general population, suggesting an important influence of
environmental and/or genetic modifying factors in muta-
tion carriers and non carriers [29]. In order to test whether
the previously listed environmental factors were of par-
ticular importance in mutation-negative females, we
assessed their influence on cancer risk in mutation-negative
female relatives of the hMLH1 c.C1528T mutation carri-
ers. This has the additional advantage that the influence of
the environmental factors on extracolonic cancer risk in
mutation-positive females can be compared more reliably,
as data on cancer risk and the influence of environmental
factors in South African females lack reliability. These
may differ from females in the western world, due to
genetic and environmental differences and the influence of
gene-environment interactions.
Aim
The aim of this study was to investigate the influence of
environmental factors on extracolonic cancer risk in South
African females and their mutation-negative relatives.
Materials and methods
In the 1980’s a database was established of individuals
with a diagnosis of colorectal cancer under the age of 50 by
a collaboration of the Colorectal Surgery Unit at Groote
Schuur Hospital and the Division of Human Genetics at the
University of Cape Town, South Africa. To date, almost
500 probands and their family members have been regis-
tered. Efforts have been made to detect the disease causing
mutations in these families. The c.C1528T mutation in the
hMLH1 gene is the most common mutation detected and
has so far been found in 15 families of mixed ancestry [26].
For the present study, all females known to be carriers of
the hMLH1 c.C1528T mutation were selected from the
database. Then, females related to these women who tested
negative for the c.C1528T mutation were selected as a
control group. At least two attempts were made to contact
each of them between August and December 2006. Data on
age, cancer history, parity and age at first and last birth
were obtained in interviews using a structured question-
naire. Information on deceased women was provided by
interviewing first-degree relatives. In addition, living par-
ticipants were interviewed regarding their age of menarche,
age of menopause, duration of breast feeding and hormonal
contraceptive use. Height and weight were measured when
possible (61% of cases).
Two families were excluded as they consisted of only
male mutation-positive members, one family was excluded
because we lost track of the only mutation-positive female
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more than 10 years ago. 94 Mutation-positive and 199
mutation-negative females from the remaining 12 families
were selected from the database. Of these, 14 mutation-
positive and 9 mutation-negative females were deceased. 7
Mutation-positive women and 78 mutation-negative
women were untraceable. The remaining 73 mutation-
positive females and 112 mutation-negative living females
were all willing to participate in the study. For the 23
deceased women, a first-degree relative was able to provide
information on parity, age at first and last birth and the
cause and date of death in all cases. Therefore, 87 muta-
tion-positive females and 121 mutation-negative females
were included in our analysis (Table 1).
The median time between data collection and cancer
diagnosis was 8 years. Pathology reports and tumour tissue
blocks were obtained where possible; this was the case in
65% of the cancers.
Ethics approval for the present study was obtained from
the Research Ethics Committee of the University of Cape
Town (REC/REF 466/2006). The majority of participants
included in the study live in remote and socio-economi-
cally challenged areas of South Africa where the postal
system is unreliable. As the collection of written consent of
all participants was not feasible, we decided to collect only
verbal consent. All living women and first degree relatives
of deceased women provided verbal consent to participate
in the study.
Statistical methods
For descriptive purposes, data was stratified by mutation
status and the presence or absence of extracolonic cancer.
These were summarised as number of women with non-
missing data, and either mean and standard deviation, or
median and range (for skewed data).
Given the small size of our cohort, the occurrence of any
extracolonic cancer, rather than specific cancers, was ana-
lysed as primary outcome measure. As the women were
closely related to one another, and their data thus not sta-
tistically independent, traditional statistical methods for
independent dichotomous variables (Chi-squared, logistic
regression) are not valid to assess the relevant associations.
Mixed-effects generalised linear models, with a binomial
family, and the default logit link were used, as they allow
us to adjust for family-relationship (as random effect) and
for other known confounders, such as age (as fixed effect).
For all our comparisons, we modelled the risk of extra-
colonic cancer as outcome, and adjusted for both age and
family membership. That means all our tests are comparing
those with extracolonic cancer to those without.
Our first analysis was to test for an association between
extra-colonic cancer risk and mutation status. We then
tested the association between extracolonic cancer risk and
each of the factors listed in Table 3, separately in the
mutation bearers and in those who do not bear that muta-
tion. The extracolonic cancer odds ratios and their 95%
confidence intervals are also given in Table 3.
Results
About 14% (12/87) of mutation-positive females reported
at least one extracolonic cancer versus 7% (8/121) of
mutation-negative females. After adjustment for age and
family of origin, this difference was statistically significant
with a P-value of 0.0279. Breast cancer was the most
common extracolonic cancer reported in mutation-positive
females, followed by endometrial cancer (Table 2).
Data on age at menarche, age at menopause, months of
breastfeeding, contraceptive use and Body Mass Index
(BMI) are summarized in Table 3. As these factors could
only be investigated in living participants, the number of
individuals and the number of extracolonic cancers in this
group were small.
The factors summarised in Table 3 were all tested for an
association with extracolonic cancer, and none were sta-
tistically significant in the mutation bearers. In the non-
mutation bearers, having used contraceptives, multiplied
the odds of ECC with 3.7, making it almost 4 times as
likely to develop a tumour if one ever used contraceptives
(compared to if one did not).
Table 1 Recruitment data
Test result Mutation-positive individuals Mutation-negative blood related individuals
Total number of individuals 94 199
Data available 87 (93%) 121 (61%)
Untraceable 7 (7%) 78 (39%)
Total number of females tested for the hMLH1 c.C1528T mutation: 317
Total number of related females tested for the hMLH1 c.C1528T mutation: 293
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Conclusion and discussion
This is the first study on the influence of environmental
factors on extracolonic cancer risk in LS mutation carriers.
We did not find a significant effect of any of the factors
investigated, namely, parity, age at first and last birth, age
at menarche and menopause, breastfeeding, contraceptive
use and BMI, after adjustment for age. A plausible expla-
nation is that the genetic influence of the LS-predisposing
mutation greatly outweighs the influence of any environ-
mental factor, especially as these cancers tend to occur at a
relatively young age when people have been exposed to
environmental factors for a relatively short period of time.
Modifying factors in cancer susceptibility syndromes
In contrast with our own findings, some previous studies on
the influence of environmental factors on colorectal cancer
risk in LS mutation carriers and cancer risk in other sus-
ceptibility syndromes detected significant associations.
With regards to LS, smoking has been associated with
an increased risk of colorectal cancer risk [10, 37] whereas
Table 2 Extra-colonic cancers in mutation-negative females
Mutation Alive Deceased All
Positive Negative Positive Negative
Number % of n Number % of n Number % of n Number % of n Number % of n
Number, n 73 112 14 9 208
Colorectal cancer 15 21 0 0 6 43 0 0 21 10
Breast cancer 4 5 2 2 3 21 2 22 11 5
Endometrial cancer 3 4 0 0 0 0 0 0 3 1
Ovarian cancer 1 1 0 0 0 0 0 0 1 0
Other cancer type 2 3 3 3 2 14 1 11 8 4
Any extracolonic cancer 7 10 5 4 5 36 3 33 20 10
Any cancer 20 27 5 4 10 71 3 33 38 18
Table 3 Descriptive statistics for investigated factors, as well as odds ratios for ECC for each of the factors
Mutation-positive Mutation-negative
Investigated factor ECC NEC OR (95% CI) ECC NEC OR (95% CI)
Number, n 12 75 8 113
Parity, median (range)1 4 (0–11) 2 (0–9) 1.1 (0.8–1.6) 3 (0–9) 2 (0–11) 1.0 (0.7–1.3)
Age at first birth, median (range)2 22 (17–25) 21 (16–41) 0.8 (0.7–1.1) 23 (20–24) 21 (16–42) 1.0 (0.7–1.2)
Age at last birth, median (range)3 40 (23–44) 29 (17–44) 1.1 (0.9–1.3) 38 (20–45) 29 (17–48) 1.0 (0.9–1.1)
Age at menarche (years, mean ± SD)4 13.8 ± 1.6 14.2 ± 1.8 1.0 (0.5–1.8) 15.5 ± 2.4 14 ± 1.9 1.3 (1.0–1.7)
Age at menopause (years, mean ± SD)5 44.0 ± 6.6 44.1 ± 5.7 0.9 (0.7–1.2) 51.8 ± 3.5 45.2 ± 6.4 1.4 (1.0–2.0)
Duration of breastfeeding (months, mean ± SD)6 22.6 ± 14.3 20.1 ± 22.0 1.0 (0.9–1.1) 92.0 ± 80.9 30.3 ± 36.1 1.0 (1.0–1.0)
Contraceptive use (ever, number (%))7 3 (25%) 55 (73%) 0.2 (0.0–1.8) 3 (38%) 8 (7%) 3.7 (1.3–10.9)
BMI (kg/m2, mean ± SD)8 34.0 ± 11.2 28.6 ± 6.9 1.0 (0.9–1.2) 31.4 ± 4.8 28.6 ± 8.1 1.1 (1.0–1.2)
For example, the odds ratio for parity, would be the odds of ECC versus NEC for each extra child. ECC extracolonic cancer. NEC no
extracolonic cancer
1 Data available for 87 mutation positive and 121 mutation negative females
2 Data available for 87 mutation positive and 121 mutation negative females
3 Data available for 80 mutation positive and 98 mutation negative females
4 Data available for 71 mutation positive and 16 mutation negative females
5 Data available for 55 mutation positive and 79 mutation negative females
6 Data available for 32 mutation positive and 42 mutation negative females
7 Data available for 41 mutation positive and 85 mutation negative females
8 Data available for 29 mutation positive and 67 mutation negative females
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fruit consumption, dietary fibre intake and the use of
aspirin were found to be protective factors [6, 10]. How-
ever, studies on the influence of consumption of alcohol,
meat and complex starch found no significant associations
with colorectal adenoma formation or cancer risk [5, 36,
37]. With the exception of the study on the influence of
aspirin and complex starch, these studies were small and
investigated a different spectrum of environmental factors
and cancers than assessed in this study.
More comprehensive research has been carried out in
BRCA mutation carriers, who are at an elevated risk for
breast and ovarian cancer. Previous research on the influ-
ence of specific environmental factors shows an important
influence of obesity, alcohol use, animal fat consumption
and physical inactivity [21]. Interestingly, the influence of
other risk factors differs from their effect in the general
population: age at menarche and menopause, important risk
factors for breast cancer in the general population, do not
significantly increase breast cancer risk in BRCA mutation
carriers [7]. With regards to oral contraceptive use, an
increase of breast cancer risk was seen for ever use and a
longer duration of use before first pregnancy [4]. The latter
is not seen in the general population, whereas a decrease of
breast cancer risk in the 10 years after stopping is seen in
the general population but not in BRCA1 and BRCA2
mutation carriers [4, 39]. We did not find an association
between age at menarche, age at menopause or oral con-
traceptive use and risk of extracolonic cancer risk in
mutation carriers, but in mutation-negative relatives, an
association was established between oral contraceptive use
and cancer risk. Although this could suggest a different
effect of oral contraceptive use in mutation carriers and non
mutation carriers, one should realize that our analysis is
complicated by the fact that we analyzed the risk of
extracolonic cancer, which in the case of mutation carriers
included both breast cancers and endometrial and ovarian
cancers and in the case of mutation-negative females
included breast cancer but no endometrial and ovarian
cancers. The latter is known to show a negative association
with oral contraceptive use, in the general population as
well as in some studies on ovarian cancer risk in BRCA1
and BRCA2 mutation carriers [8, 20, 22]. Nevertheless, a
final advice on whether to use oral contraceptives should be
based on overall cancer risk.
As mentioned previously, it has been assumed that
mutation negative-relatives of carriers of cancer suscepti-
bility genes might show an increased risk of cancer due to
the influence of modifier genes and environmental factors,
which makes these families prone to develop cancer and
therefore more likely to be screened for mutations involved
in cancer susceptibility genes [25, 29]. However, in our
cohort, we could only establish a relationship between oral
contraceptive use and cancer risk in mutation-negative
females.
Risk of extracolonic cancer
In the present analysis, mutation-positive females had a
significant higher risk of extracolonic cancer compared to
their mutation-negative sisters. This result is in contradic-
tion with our previous report, where a Fisher’s exact test
was used to analyse the data and no significant difference
was found. As discussed in the ‘‘Materials and Methods’’
section, this test was not valid for our study design and
therefore the results of the present analysis replace the
previous one. We conclude that hMLH1 c.C1528T muta-
tion carriers are at an elevated risk for extracolonic cancer
with an Odd’s ratio of 3.33 (95%CI: 1.11–10.00). Still, this
risk seems to be lower than previously reported in other
families.
Limitations
Several limitations can be recognized in the present study.
Most importantly, the study was constrained by the small
size of the cohort and more importantly by the low fre-
quency of extracolonic cancers. It is possible that associ-
ations exist, but that our study did not have enough power
to detect them. As a consequence, we were not able to
analyze the influence of the investigated environmental
factors on specific cancer types. Furthermore, the scope of
this study was limited to females and extracolonic cancer,
with a focus on ‘gynaecological factors’, instead of the
complete LS tumor spectrum in mutation carriers of both
sexes. Lastly, as the extracolonic tumour spectrum in our
cohort differs from most other families described, they will
probably display a different spectrum of environmental
factors that influence cancer risk and one can therefore
question the possibility of applying our findings to other
families.
Although these limitations are serious, we believe that
the strength of the present study is the uniqueness of the
relatively large ‘homogeneous’ cohort, as well as its
attempt to contribute to a more comprehensive approach of
risk management in LS-mutation carriers. Longitudinal
follow-up of the c.C1528T cohort might provide us with
additional data as the number of mutation carriers and the
incidence of extracolonic cancer will rise with time. In
addition, further research on the influence of environmental
factors in cohorts known to have a high incidence of ex-
tracolonic cancer, e.g. in hMLH6 mutation carriers, would
be worthwhile. Furthermore, investigations of the influence
of other environmental factors on CRC and extracolonic
cancer risk should be expanded.
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Conclusion
In conclusion, no effect of any of the investigated risk
factors on extracolonic cancer risk in LS mutation carriers
was found in the present study. The effect of environmental
factors on disease expression in LS mutation carriers is
scarcely investigated. Therefore, this study should be taken
as a motivation for further research. Knowledge of the
impact of modifiable factors on cancer risk might enable us
to provide mutation carriers with evidence-based lifestyle
counselling, thereby complementing the prevention strate-
gies available today. Only a broad strategy involving pri-
mary and secondary prevention methods will offer
mutation carriers the best prospective possible outcomes.
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